Notably, they demonstrated that recognition of HNSCC cells by EGFR853-861-specific T cells was enhanced by incubation of tumor cells with the EGFR-blocking monoclonal antibody (mAb) cetuximab, which might facilitate antigen presentation through enhanced internalization and proteasomal degradation of EGFR (Vincenzi et al., 2008) and STAT-1-induced HLA class I upregulation (Srivastava et al., 2015). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.